JP2022503792A5 - - Google Patents
Info
- Publication number
- JP2022503792A5 JP2022503792A5 JP2021516496A JP2021516496A JP2022503792A5 JP 2022503792 A5 JP2022503792 A5 JP 2022503792A5 JP 2021516496 A JP2021516496 A JP 2021516496A JP 2021516496 A JP2021516496 A JP 2021516496A JP 2022503792 A5 JP2022503792 A5 JP 2022503792A5
- Authority
- JP
- Japan
- Prior art keywords
- caution
- optionally substituted
- alkyl
- independently
- membered heterocycles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736974P | 2018-09-26 | 2018-09-26 | |
| US62/736,974 | 2018-09-26 | ||
| PCT/US2019/053015 WO2020069027A1 (en) | 2018-09-26 | 2019-09-25 | Treatment of hematological malignancies with inhibitors of menin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022503792A JP2022503792A (ja) | 2022-01-12 |
| JP2022503792A5 true JP2022503792A5 (enExample) | 2022-10-04 |
Family
ID=69949505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516496A Pending JP2022503792A (ja) | 2018-09-26 | 2019-09-25 | メニン阻害剤を用いた血液悪性腫瘍の処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20230095934A1 (enExample) |
| EP (1) | EP3856173A4 (enExample) |
| JP (1) | JP2022503792A (enExample) |
| CN (1) | CN113164443A (enExample) |
| WO (1) | WO2020069027A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109415337B (zh) | 2016-05-02 | 2022-01-18 | 密执安大学评议会 | 作为多发性内分泌腺瘤蛋白抑制剂的哌啶 |
| ES2831084T3 (es) | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| EP3600313A4 (en) | 2017-03-31 | 2020-09-23 | The Regents of The University of Michigan | PIPERIDINES AS COVALENT MENINE INHIBITORS |
| AU2019227607C1 (en) | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CN117304191A (zh) | 2018-07-05 | 2023-12-29 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| UY38988A (es) * | 2019-12-19 | 2021-06-30 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal |
| IL297039A (en) | 2020-04-07 | 2022-12-01 | Syndax Pharmaceuticals Inc | Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof |
| CN114478568A (zh) * | 2020-10-27 | 2022-05-13 | 苏州优理生物医药科技有限公司 | 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用 |
| KR20230142745A (ko) | 2021-01-29 | 2023-10-11 | 세딜라 테라퓨틱스, 인크. | Cdk2 억제제 및 그의 사용 방법 |
| BR112023021040A2 (pt) * | 2021-05-08 | 2024-02-06 | Janssen Pharmaceutica Nv | Derivados espiro substituídos |
| EP4334310A1 (en) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituted spiro derivatives |
| AU2022274071A1 (en) * | 2021-05-11 | 2024-01-04 | Janssen Pharmaceutica Nv | Combination therapies |
| KR20240006638A (ko) * | 2021-05-11 | 2024-01-15 | 얀센 파마슈티카 엔브이 | 조합 요법 |
| AR125866A1 (es) | 2021-05-14 | 2023-08-23 | Syndax Pharmaceuticals Inc | Inhibidores de la interacción de menina-mll |
| CA3218479A1 (en) | 2021-06-01 | 2022-12-08 | Wei Cai | Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives |
| WO2022253289A1 (en) | 2021-06-03 | 2022-12-08 | Janssen Pharmaceutica Nv | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
| WO2022257047A1 (en) * | 2021-06-09 | 2022-12-15 | Acerand Therapeutics (Hong Kong) Limited | Diazaspirobicylic compounds as protein-protein interaction inhibitors and applications thereof |
| AU2022292697A1 (en) | 2021-06-17 | 2024-02-01 | Janssen Pharmaceutica Nv | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
| TW202317560A (zh) | 2021-06-26 | 2023-05-01 | 美商賽迪拉治療股份有限公司 | Ｃｄｋ２抑制劑及其使用方法 |
| MX2024007201A (es) * | 2021-12-15 | 2024-08-06 | Dana Farber Cancer Inst Inc | Direccionamiento terapeutico del tumor del estroma gastrointestinal (gist) mediante la alteracion del complejo epigenetico de menina-mll. |
| WO2023150635A1 (en) * | 2022-02-04 | 2023-08-10 | Kura Oncology, Inc. | Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| CN120514709A (zh) * | 2022-05-09 | 2025-08-22 | 赛达克斯制药股份有限公司 | 用于治疗癌症的menin-mll抑制剂 |
| WO2024046457A1 (en) * | 2022-09-02 | 2024-03-07 | Hutchmed Limited | Triazine compounds and uses thereof |
| CN120456907A (zh) * | 2022-11-02 | 2025-08-08 | 库拉肿瘤学公司 | 急性白血病的治疗方法 |
| WO2024112819A1 (en) * | 2022-11-22 | 2024-05-30 | Dana-Farber Cancer Institute, Inc. | Men1 mutations and uses thereof |
| US20260151399A1 (en) * | 2022-11-24 | 2026-06-04 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| AR132185A1 (es) | 2023-03-24 | 2025-06-04 | Acerta Pharma Bv | COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA |
| CN118994033B (zh) * | 2023-05-17 | 2025-09-16 | 成都先导药物开发股份有限公司 | 一种sdnx-5613的合成方法及其中间体化合物 |
| IL325861A (en) * | 2023-07-17 | 2026-03-01 | Kura Oncology Inc | Crystalline forms of a menin inhibitor |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017514505A (ja) * | 2014-05-07 | 2017-06-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 急性骨髄性白血病の新規バイオマーカー |
| USRE49687E1 (en) * | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| TWI703150B (zh) * | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| CA2998042C (en) * | 2015-09-14 | 2022-07-05 | Brunangelo Falini | Dactinomycin compositions and methods for the treatment of acute myeloid leukemia |
| AU2017212572A1 (en) * | 2016-01-26 | 2018-08-23 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| US10752639B2 (en) * | 2016-03-16 | 2020-08-25 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| WO2017161028A1 (en) * | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| CN109415337B (zh) * | 2016-05-02 | 2022-01-18 | 密执安大学评议会 | 作为多发性内分泌腺瘤蛋白抑制剂的哌啶 |
| CA2937896A1 (en) * | 2016-08-02 | 2018-02-02 | Universite De Montreal | Use of mubritinib for the treatment of poor prognosis acute myeloid leukemia |
| WO2018024602A1 (en) * | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| KR20180074792A (ko) * | 2016-11-02 | 2018-07-03 | 아로그 파마슈티칼스, 인코퍼레이티드 | 돌연변이 연관된 flt3 돌연변이된 증식성 장애를 치료하기 위한 크레노라닙 |
| WO2018106820A1 (en) * | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| JP7193460B2 (ja) * | 2016-12-23 | 2022-12-20 | プレキシコン インコーポレーテッド | Ｃｄｋ８調節およびその適応症のための化合物および方法 |
| CN110691779B (zh) * | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
-
2019
- 2019-09-25 JP JP2021516496A patent/JP2022503792A/ja active Pending
- 2019-09-25 CN CN201980078019.9A patent/CN113164443A/zh active Pending
- 2019-09-25 EP EP19867072.1A patent/EP3856173A4/en active Pending
- 2019-09-25 WO PCT/US2019/053015 patent/WO2020069027A1/en not_active Ceased
- 2019-09-26 US US17/278,527 patent/US20230095934A1/en not_active Abandoned
-
2025
- 2025-09-11 US US19/326,618 patent/US20260216190A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6952097B2 (ja) | ラミノパシー、老化及び癌を治療又は予防するためのｎａｔ１０モジュレーター | |
| CN104000806B (zh) | 端粒酶活化化合物及其使用方法 | |
| CN116354960A (zh) | Shp2磷酸酶抑制剂 | |
| JP2020514388A5 (enExample) | ||
| EP2853293B1 (en) | Thioninium compounds and their use | |
| US11654149B2 (en) | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies | |
| CN113164443A (zh) | 用多发性内分泌抑癌蛋白抑制剂治疗血液系统恶性肿瘤 | |
| JP2019521988A (ja) | 癌を処置するためのｅｚｈ２阻害剤 | |
| JP2018524298A (ja) | リンパ腫を処置するためのｅｚｈ２阻害剤 | |
| ZA200105399B (en) | Tricyclic inhibitors of poly(ADP-ribose) polymerases. | |
| EP1423080A2 (en) | Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors | |
| JP7747351B2 (ja) | ベンゼン環化合物及びその使用 | |
| CA3246041A1 (en) | Tetracyclic compound and its use | |
| WO2018200571A1 (en) | Substituted 2,3-dihydro-1h-indene analogs and methods using same | |
| EP0512817A1 (en) | Pyridazinedione derivatives, their preparation and pharmaceutical applications | |
| JP2023524230A5 (enExample) | ||
| WO2021097075A1 (en) | Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same | |
| RU2025136491A (ru) | Производное 3,4-дигидрофталазин-1(2h)-она, способ его изготовления и его применение | |
| JP3718533B2 (ja) | ジヒドロキシフェニルスルフィド誘導体またはその塩を含む抗メラノーマ剤 | |
| EA047636B1 (ru) | Соединения и способы их применения | |
| WO2023002323A1 (en) | Synthesis of substituted tricyclic amides and analogues thereof | |
| AU2022399786A1 (en) | Compounds | |
| AU2023366352A1 (en) | New inhibitors of phosphatidylinositol 3-kinase | |
| HK40105830A (en) | Compositions and methods for treating anemia associated with a ribosomal disorder | |
| IE42878B1 (en) | 4-amino-3-benzylideneamino-1,2,4-triazoles-methods for their preparation and their use |